Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.35, $0.01 worse than the analyst estimate of $0.36. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.54 billion.

"Our global team and differentiated portfolio enabled us to deliver good sales and earnings growth this quarter, despite some revenue softness compared to our estimates," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "With our strong pipeline and category leadership strategy, we are confident in our top tier 2019 outlook and how we can help improve outcomes for patients around the world for years to come."

GUIDANCE:

Boston Scientific sees FY2019 EPS of $1.54-$1.58, versus the consensus of $1.56.

Boston Scientific sees Q2 2019 EPS of $0.37-$0.39, versus the consensus of $0.39.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.